GlobeNewswire
-
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026 -
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
27/07/2026 -
Applied Biologics Announces Extension of Longstanding System-Wide Agreement With Providence Health & Services for XWRAP®
27/07/2026 -
Oktopi secures follow-on funding to expand OktoPilot's AI-informed capabilities, building on the inaugural global health grant
27/07/2026 -
Assisting Hands Home Care Frisco Trains Caregivers in Stroke Recovery, Brings Post-Stroke Education to North Texas Families
27/07/2026 -
Micron Biomedical Secures $4.5 Million Federal Contract to Develop First Dissolvable Microarray Radiation/Nuclear Medical Countermeasure
27/07/2026 -
Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
27/07/2026 -
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026 -
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026 -
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026 -
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026 -
Picard Medical Receives NYSE American Acceptance of Compliance Plan
27/07/2026 -
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
27/07/2026 -
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27/07/2026 -
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
27/07/2026 -
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
27/07/2026 -
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
27/07/2026 -
Novo Nordisk A/S - share repurchase programme
27/07/2026 -
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc.
27/07/2026
Pages